Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
North America Canada Market Access

'Status Quo' Interim Pricing Guidance Now In Force In Canada

  • News

Executive Summary

Provisional guidance on controversial pricing reforms is now in place in Canada.

You may also be interested in...



Canada Tackles Pricing Review Backlog With New Interim Guidance

Canada’s Patented Medicine Prices Review Board is consulting on further draft interim guidance on pricing to expedite reviews of medicines authorized since July 2022.

Canada’s Controversial Pricing Guidelines Suspended

The implementation of new pricing guidelines that are unpopular with the pharmaceutical has been put on hold, to the relief of the pharmaceutical industry.

Canadian Guideline Homes In On Excessive Medicine Pricing

New draft guidelines outlining how Canada’s drug pricing authority will decide whether to investigate if a medicine is excessively priced are now out for consultation.

Table

View full table

Related Content

Pink Sheet
Pink Sheet

Topics

Tags:
North America Canada Market Access
Latest Headlines

Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification

US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios

FTC Early Findings In PBM Investigation Coming By Mid-Summer, Chair Kahn Says

New EU Filings

See All
UsernamePublicRestriction

Register

PS146906

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By